S100A4 and cardiomyopathy: Hence, it is plausible that the release of TFs FOS, FOSB, and JUNB by C6 S100A4+ SMCs contributes to exacerbating cardiomyopathies, potentially through the induction of cardiac fibrosis and inflammation.